- QURE is a leader in gene therapy, and has the first commercially licensed gene therapy manufacturing facility.
- Utilizing their industry leading technology, they are developing treatments and cures for genetic diseases (e.g., Huntington's and hemophilia B).
- They have inked a $1.6 B commercialization agreement with CLS Behring for exclusive rights to sell gene therapy for hemophilia B.
- Successful commercialization of their technology will be life changing for many people, and a financial blockbuster for shareholders.
- It's worth a watchlist consideration for an investor who is looking for high risk-high reward scenario.
For further details see:
UniQure: Leading Gene Therapy Company